ALS Biologics

ALS Biologic is a clinical-stage biotechnology company dedicated to developing innovative treatments for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative disorders. The company focuses on modulating neuroinflammation and neuroprotection pathways to slow disease progression. Its lead program, ALS-001, is a small molecule candidate targeting the Prostaglandin E2 receptor 4 (EP4) to address the underlying mechanisms of motor neuron degeneration. ALS Biologic leverages a deep understanding of disease pathophysiology to advance its pipeline through clinical development. The company is headquartered in Lille, France, and operates within a robust ecosystem of European life science research.